Table 5.
Correlation coefficients between characteristics, questionnaires scores and urinary symptoms, uroflowmetry parameters, and urinary beta 3-adrenoceptor/Cr levels in OAB patients with and without 12-week mirabegron treatment.
| Urinary beta 3-adrenoceptor/Cr (pg/mg) | |||
|---|---|---|---|
| Non-treated OAB before treatment (n = 27) | Treated OAB before treatment (n = 23) | Treated OAB after treatment (n = 23) | |
| rs | rs | rs | |
| Age (y) | 0.174 | 0.292 | 0.407 |
| BMI (kg/m2) | − 0.170 | 0.424* | − 0.171 |
| Parity | − 0.047 | 0.361 | 0.391 |
| OABSS | − 0.055 | 0.143 | − 0.299 |
| OAB-qSF symptom bother | − 0.003 | 0.211 | − 0.347 |
| OAB-qSF HRQL | 0.136 | 0.403 | − 0.431* |
| SF-12 | 0.136 | − 0.044 | − 0.312 |
| GRAS | 0.000 | 0.000 | 0.367 |
| Micturitions/24 h | − 0.151 | 0.091 | − 0.112 |
| Urgency episodes/24 h | − 0.133 | 0.162 | − 0.385 |
| Uroflowmetry | |||
| Qmax (mL/s) | 0.007 | − 0.177 | 0.244 |
| Capacity (mL) | 0.161 | 0.052 | − 0.190 |
| RU (mL) | 0.114 | 0.310 | − 0.210 |
OAB, Overactive bladder; BMI, Body mass index; OABSS, Overactive Bladder Symptom Score; OAB-qSF, Overactive Bladder Questionnaire Short Form; HRQL, health-related quality of life scales; SF-12, Short Form Survey-12; GRAS, Global Response Assessment Scale; Qmax, maximum flow rate; RU, residual urine.
rs: Spearman's correlation coefficient.
*p < 0.05.